🔴 Lipocine is trading 5% down today amid biotech-sector weakness

Lipocine is trading at $1.59, down 5.36%, amid biotech-sector weakness; no confirmed company-specific catalyst has surfaced.

• No company-specific announcement explaining the October 16 decline appeared in the available search results.
• Biotech ETF XBI is down 2.06%, amid rotation away from higher-risk growth stocks; the Nasdaq Composite is down more than 1% in the supplied market context.
• Available evidence points to sector and market sentiment, not a confirmed Lipocine-specific catalyst.